PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsnewborn respiratory distress syndrome
MeSH D012127 - newborn respiratory distress syndrome
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D012128:Respiratory distress syndrome
51 Companies
6 Drugs
$
Success rate
D007235:Premature infant diseases
0 Companies
0 Drugs
Success rate
D012127: 
Newborn respiratory distress syndrome
7 Companies
6 Drugs
$
Success rate
D006819:Hyaline membrane disease
0 Companies
0 Drugs
Success rate
D059245:Transient tachypnea of the newborn
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
AbbVieBeractant Survanta  1991-07-01   
Chiesi FarmaceuticiPoractant alfa Curosurf  1999-11-18   
Linde HealthcareNitric oxide INOmax  2001-08-01   
MallinckrodtNitric oxide INOmax 2029-06-30 1999-12-23 $118.3 M Y2016 
ONY BiotechCalfactant Infasurf  1998-07-01   
Vero BiotechNitric oxide Genosyl 2022-02-23 2019-12-20   
Clinical Trials
Historical Success Rate
Phase 1
25%
1/4
Phase 2
33%
2/6
Phase 3
86%
6/7
Approved: 4Overall Success rate: 7%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Chiesi Farmaceutici
Poractant alfa,
Aspartame,
Hyoscyamine,
Atropa belladonna,
CHF5633
GSK
GSK2862277
Mallinckrodt
Nitric oxide,
Enoblituzumab
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use